Johnson & Johnson (JNJ) Q1 2025: Diversified Model Delivers Growth Despite Stellara Erosion and Margin Headwinds
Johnson & Johnson’s Q1 2025 results highlight the company’s ability to deliver operational growth in both Innovative Medicine and MedTech, even as the loss of exclusivity (LOE) for Stellara and margin pressures weigh on results. Strategic pipeline execution, new product launches, and disciplined capital allocation underpin management’s confidence in full-year guidance and long-term upside.
Summary
- Operational Growth Amidst Headwinds: Q1 sales rose 4.2% operationally to $21.9 billion, overcoming an 810 basis point drag from Stellara LOE.
- Pipeline and Portfolio Momentum: Double-digit growth from 11 key brands and continued MedTech expansion offset biosimilar and pricing pressures.
- Margin Compression and Tariff Impact: Gross margin contracted due to mix shift, Part D redesign, and $400 million in tariffs, with management signaling partial recovery ahead.
- Capital Allocation Discipline: $3.4 billion in free cash flow, a 4.8% dividend increase, and $55 billion in U.S. investment reinforce long-term commitment.
Performance Analysis
Johnson & Johnson posted Q1 2025 worldwide sales of $21.9 billion, up 4.2% operationally, despite a significant 470 basis point headwind from Stellara, the company’s former multi-billion-dollar immunology blockbuster facing biosimilar competition. U.S. sales grew 5.9%, while ex-U.S. sales rose 2.1%. Adjusted net earnings reached $6.7 billion with adjusted EPS of $2.77, both up modestly year-over-year. The headline net earnings of $11 billion and EPS of $4.54 reflect a $7 billion talc reserve reversal, a non-recurring benefit.
Innovative Medicine delivered $13.9 billion in sales, up 4.2%, even as Stellara’s 32.3% decline reduced sector growth by 810 basis points. Notably, Darzalex, a multiple myeloma therapy, grew 22.5%, and Carvicti and other oncology assets posted triple-digit gains. Immunology standout Tremfya rose 20.1%, offsetting Stellara’s erosion. MedTech sales increased 4.1% to $8 billion, with cardiovascular businesses Abiomed and Shockwave contributing double-digit growth, though orthopedics declined 3.1% due to one-time events and competitive pressure.
- Gross Margin Squeeze: Cost of product sold deleveraged by 320 basis points, mainly from Stellara’s decline, tariffs, and product mix shift.
- Resilient Cash Generation: Free cash flow was $3.4 billion, supporting ongoing R&D and shareholder returns.
- Dividend Commitment: The 63rd consecutive annual dividend increase, up 4.8%, underscores capital return discipline.
Management’s reaffirmed guidance and focus on portfolio renewal signal confidence in navigating near-term margin and pricing headwinds, while pipeline execution and new launches are expected to drive acceleration in the second half.
Executive Commentary
"No other healthcare company has delivered growth through the first year of losing exclusivity for a multi-billion dollar product. In our case, Stellara. And yet, that is exactly what we are doing. Our resiliency is a testament to what makes us unique."
Joaquin DeWato, Chairman and CEO
"We are increasing our operational sales guidance for the full year by $700 million to reflect the addition of CapLIDA following the completion of the intercellular acquisition. We are maintaining our adjusted reported earnings per share guidance of 6.2% at the midpoint for a range of $10.50 to $10.70."
Joe Walk, Chief Financial Officer
"TREMFIA continues to offer an exceptional solution for patients struggling with inflammatory bowel disease. We are absolutely thrilled with the progress that our pipeline has made in the first quarter of this year."
John Reed, EVP, Innovative Medicine R&D
Strategic Positioning
1. Diversified Business Model Shields Against Patent Expiry
JNJ’s unique blend of pharmaceuticals (Innovative Medicine) and MedTech provides operational resilience, as evidenced by continued growth despite Stellara’s LOE. While most peers see contraction after losing exclusivity on a major drug, JNJ’s diversified revenue base and broad pipeline blunt the impact.
2. Pipeline Execution and Portfolio Renewal
Eleven key brands posted double-digit growth, led by Darzalex, Carvicti, and Tremfya. Recent launches in IBD and oncology, plus the acquisition of intracellular therapies (Caplida), strengthen the portfolio with multiple $5 billion-plus peak sales assets. MedTech growth is fueled by cardiovascular expansion (Abiomed, Shockwave) and innovation in robotic surgery and vision care.
3. Margin Management Amid Tariffs and Mix Shift
Gross margin contracted due to Stellara’s decline, unfavorable mix, and $400 million in tariffs, primarily from MedTech and China. Management expects some recovery as new launches scale and cost actions take hold, but pricing power remains limited by contracts and regulation.
4. Capital Allocation and U.S. Investment
JNJ’s $55 billion U.S. investment plan over four years aims to localize advanced medicine manufacturing, reduce supply chain risk, and secure future growth. The company maintains disciplined R&D investment (15% of sales), ongoing M&A, and consistent dividend growth.
5. Strategic Response to Regulatory and Legal Headwinds
The reversal of the talc reserve and ongoing litigation management have not impaired JNJ’s capital priorities. Management is proactive in engaging with U.S. policy on tariffs and manufacturing, advocating for tax policy over tariffs to drive domestic production and supply chain security.
Key Considerations
JNJ’s Q1 demonstrates the power and limitations of a diversified healthcare model as it navigates patent cliffs, regulatory change, and global cost volatility.
Key Considerations:
- Stellara Erosion Offset by Pipeline: The 810 basis point drag from Stellara is being countered by rapid growth in Tremfya, Darzalex, and new launches, but the full-year impact will accelerate as biosimilar competition intensifies.
- MedTech Innovation and Execution: Cardiovascular and surgical vision are outperforming, though orthopedics faces transitory and competitive headwinds. Product launches and restructuring are expected to drive a stronger second half.
- Tariff and Margin Watch: $400 million in tariffs, especially from China, will pressure MedTech margins. JNJ’s limited price leverage means cost actions and supply chain localization are critical for mitigation.
- Capital Allocation Consistency: $3.4 billion in free cash flow, a robust balance sheet, and a 4.8% dividend hike reinforce JNJ’s shareholder return commitment amid legal and macro uncertainties.
- Recession Resilience: Healthcare demand remains stable, though elective procedures (notably in orthopedics) could see temporary delays if economic conditions deteriorate.
Risks
Stellara’s LOE and biosimilar erosion will intensify through 2025, placing pressure on both top-line growth and gross margin. Tariff exposure, especially for MedTech exports to China, remains fluid and could worsen with further policy shifts. Margin recovery depends on successful scaling of new launches and execution of cost initiatives, while pricing power remains constrained. Regulatory and legal uncertainties, including ongoing talc litigation, could introduce further volatility.
Forward Outlook
For Q2 and the remainder of 2025, JNJ guided to:
- Operational sales growth of 3.3% to 4.3% (midpoint $92 billion), up $700 million due to Caplida acquisition
- Reported sales growth of 2.6% to 3.6% (midpoint $91.4 billion), reflecting currency headwinds
- Adjusted EPS of $10.50 to $10.70, unchanged despite dilution from recent M&A and tariffs
Management expects higher growth in both segments in the second half, as new launches ramp and MedTech recovers from one-time events. Tariff and Stellara headwinds will be most acute in 2025 but are expected to moderate as portfolio renewal and cost actions take effect.
Takeaways
JNJ’s Q1 2025 results reinforce the value of a diversified healthcare platform able to withstand patent cliffs and regulatory headwinds.
- Portfolio Depth Offsets Patent Cliff: Double-digit growth from key brands and MedTech innovation are cushioning the impact of Stellara’s biosimilar erosion, validating management’s long-term growth thesis.
- Margin and Tariff Pressure Will Persist: Near-term gross margin compression and tariff exposure require careful monitoring, as pricing power is limited and mitigation strategies will take time to materialize.
- Pipeline and Capital Allocation Are Core Levers: Continued R&D investment, disciplined M&A, and a robust dividend signal management’s commitment to long-term value creation and risk management.
Conclusion
JNJ’s Q1 performance demonstrates resilience and adaptability in a challenging macro and competitive landscape. While margin and tariff headwinds will persist in the near term, the company’s diversified model, pipeline momentum, and disciplined capital allocation provide a credible path to sustained growth and shareholder value.
Read-Through
For the broader healthcare sector, JNJ’s results highlight the importance of portfolio diversification, pipeline execution, and proactive supply chain localization in managing patent cliffs, regulatory shifts, and geopolitical cost risks. The accelerating biosimilar impact on legacy blockbusters is a warning for other large pharma peers, while MedTech’s tariff exposure and margin compression are likely to be echoed across the industry. The continued prioritization of R&D, M&A, and U.S. manufacturing expansion signals where leadership is focused to secure long-term growth in a volatile environment.